BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

Blood

Volumn 111, Issue 3, 2008, Pages 1101-1109

  Niesvizky, Ruben ^a   Jayabalan, David S ^a   Christos, Paul J ^a   Furst, Jessica R ^a   Naib, Tara ^a   Ely, Scott ^a   Jalbrzikowski, Jessica ^a   Pearse, Roger N ^a   Zafar, Faiza ^a   Pekle, Karen ^a   LaRow, April ^a   Lent, Richard ^a   Mark, Tomer ^a   Cho, Hearn J ^a   Shore, Tsiporah ^a   Tepler, Jeffrey ^a   Harpel, John ^a   Schuster, Michael W ^a   Mathew, Susan ^a   Leonard, John P ^a   Mazumdar, Madhu ^a   Chen Kiang, Selina ^a   Coleman, Morton ^a   more..

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DEXAMETHASONE; LENALIDOMIDE; M PROTEIN;

ADULT; AGED; ANEMIA; ANOREXIA; APPETITE DISORDER; ARTICLE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DIVERTICULOSIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPONATREMIA; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE SPASM; MUSCLE WEAKNESS; MYOPATHY; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RASH; SEPSIS; SIDE EFFECT; SYMPTOMATOLOGY; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TREMOR; VISUAL DISORDER;

EID: 38949216066     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-090258     Document Type: Article

References (44)

1. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
2. Coleman M, Silver RT. The chemotherapy of plasma cell myeloma and related disorders. Antibiot Chemother. 1974;18:112-147.
3. Palumbo A, Bringhen S, Caravita T, et al; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-831.
4. Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan - prednisone (MP) - thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. Blood. 2005;106. Abstract 780.
5. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
6. Niesvizky R, Siegel D, Glassman J, et al. Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. Leuk Lymphoma. 2002;43:607-612.
7. Rajkumar SV. Multiple myeloma: the death of VAD as initial therapy [comment]. Blood. 2005;106:2-3.
8. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003;121:768-771.
9. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887-890.
10. Cavo M, Zamagni E, Tosi P, et al; Bologna 2002 Study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39.
11. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
12. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
13. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436.
14. Coleman M, Leonard J, Lyons L, et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma. 2002;43:1777-1782.
15. Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenström's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol. 2003;30:270-274.
16. Spahn JD, Fost DA, Covar R, et al. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol. 2001;87:501-505.
17. Durie BG, Villarete L, Farvard A, et al. Clarithromycin (Biaxin) as primary treatment for myeloma [abstract]. Blood. 1997;10 (suppl 1):579a.
18. Vescio RA, Sjak-Shie NN, Manyak SJ, Yang H, Berenson JR. Clarithromycin (Biaxin) adds to the efficacy and toxicity of steroid therapy in multiple myeloma [abstract]. Blood. 2001;98. Abstract 5007.
19. Niesvizky R, Pekle K, Lyons L, et al. Dexamethasone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin) on response rate. Interim results of a prospective, sequential, randomized trial [abstract]. Blood. 2003;102. Abstract 832.
20. Niesvizky R, Bergsagel PL, Pearse RN, et al. Clarithromycin potentiates the response to dexamethasone in chemotherapy naive multiple myeloma patients: a prospective, sequential, randomized trial [abstract]. Blood. 2002;100:389b.
21. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H, Hibi T. Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res. 2004;24:3723-3730.
22. Nakamura M, Kamimoto T, Yoshimori T, Mitsuya H, Hata H. Clarithromicin induces autophagy in myeloma cells [abstract]. Blood. 2006;108. Abstract 3509.
23. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322.
24. Dimopoulos MA, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. Blood. 2005;106. Abstract 6.
25. Weber D, Wang M, Chen C, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function [abstract]. Blood. 2006;108. Abstract 3547.
26. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050-4053.
27. Durie BG, Harousseau JL, Miguel JS, et al International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
28. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
29. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
30. Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematology. 2007;138:640-643.
31. Lacy M, Gertz M, Dispenzieri A, et al. Long term results of response to therapy, time to progression and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clinic Proc. 2007;82:1179-1184.
32. Moreau P, Huynh A, Facon T, et al. Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM). Leukemia. 1999;13:490-491.
33. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carotenuto M, Carella AM. Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report. Haematologica. 2002;87:658-659.
34. Stewart AK, Trudel S, Al-Berouti BM, Sutton DM, Meharchand J. Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. Blood. 1999;93:4441.
35. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood. 2007;110. Abstract 74.
36. Low-dose steroid combined with lenalidomide prolongs survival compared with high-dose steroid for multiple myeloma treatment [press release]. Bethesda, MD: NCI; April 4, 2007. Available: http://www.cancer.gov/newscenter/ pressreleases/MultipleMyelomaDexamethasone. Accessed September 4, 2007.
37. Attal M, Harousseau JL, Facon T, et al; Inter-Groupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
38. Palumbo A, Bringhens S, Caravita T, et al; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-831.
39. Facon T, Mary J, Harousseau J, et al; Inter-Groupe Francophone du Myélome. Superiority of melphalan-prednisone (MP) - thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. J Clin Oncol. 2006;24(18 suppl):1.
40. Niesvizky R, Martinez-Banos DM, DeSancho TM, et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma. 2007;48:2330-2337.
41. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004;126:715-721.
42. Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy [letter]. Leukemia. 2004;18:2044-2046.
43. Niesvizky R, Pekle K, Gelbshtein U, et al. BiRD (Biaxin®/ Revlimid®/dexamethasone) combination therapy (Rx) results in high complete remissions (CR) and overall responses in myeloma (MM) with poor prognostic features. Blood. 2005;106: Abstract 642.
44. Niesvizky R, Jayabalan DS, Furst JR, et al. Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma. J Clin Oncol. 2006;24(18 Suppl):7545.